ESMO Immuno-Oncology 2025 | Neoadjuvant immunotherapy strategies for challenging endometrial cancer

Yeah, this is, of course, really, really important because endometrial cancer has not been given as much prime time in the overall analysis in the human setting. And these are some of those very challenging cancers where, again, immunotherapy or any other therapeutic setting remains very heterogeneous. I think I’m quite happy to see that the neoadjuvant setting is now starting to also help these cancer types, which have not been at the forefront of the progress. We’ve heard more about lung cancer, colorectal cancer all the time, but very little about these kinds of cancers. So that study is also interesting. They also see some of these very B-cell-driven analyses about tertiary lymphoid structures and these kinds of signaling pathways. So I’m actually quite glad to be able to discuss that study in the bigger perspective of how endometrial cancer behaves and hopefully can shed light on how these studies can be contextualized in the more multimodal immunotherapy approach, because I don’t think immunotherapy alone would be enough for some of these challenging cancers because they don’t have enough antigen momentum, let’s put it like that. And so it would be interesting to discuss what else might be needed to make it work.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.